Almirall reaches an agreement to acquire 100% of Poli Group

Poli Group comprises three operating companies —Taurus Pharma GmbH, Polichem SA and Polichem Srl.

Poli Group has a diversified and growing portfolio of proprietary and well-established drugs, focused on dermatology and complemented with a strong portfolio of gynaecology and respiratory products, the latter promoted through distributors. The acquired brands include Ciclopoli, the flagship product that has led Poli Group to become a world leader in nail diseases (onychomycosis), a large and underserved market affecting approximately 10–15% of the total population. Other main dermatology products include Sililevo and Zeloglin, used to treat nail psoriasis and rosacea.

Poli Group's products are commercialised in 70 countries, with a focus on Europe and Asia. For the last 12 months, ending in June 2015, the company generated net sales close to ~€85m. The company has 85 employees.

This acquisition is the next step in the strategic evolution of Almirall, moving further into a specialty pharma model focused on dermatology. Through the acquisition Almirall will

Jorge Gallardo, President of Almirall, commented: "This important transaction is the result of our continued focus on growing our presence in the global Dermatology market. The products of Poli Group will provide Almirall with leading market positions in key geographies in which we want to increase our footprint. We still have room to grow in Dermatology and will continue to analyse opportunities in the market."